



## Gene Security Network Names Jason Nestor Vice President of Sales

REDWOOD CITY, Calif.—October 14, 2009--Gene Security Network, Inc. (GSN), a privately held molecular diagnostics company with a novel testing technique for preimplantation genetic diagnosis (PGD) –*24 Chromosome Screening with Parental Support™*, today announced that it has appointed Jason Nestor as its Vice President of Sales.

Mr. Nestor comes to GSN with over 25 years of pharmaceutical sales experience in the fertility and reproductive endocrinology marketplace and a demonstrated record of building sales organizations with a consistent pattern of sales growth. He is well known in the fertility industry with longstanding relationships with leading reproductive endocrinologists in North America. Most recently, Mr. Nestor served as Executive Director of Sales for Ferring Pharmaceuticals, where he was responsible for establishing Ferring's sales presence, ultimately achieving annual revenues of over \$100 million in the United States. Prior to Ferring, Mr. Nestor held various positions at the Ares-Serono Group where he established Serono's sales presence in the United States in 1982 and built the company's Canadian operations. Mr. Nestor was ultimately promoted to General Manager and President in 1989 to oversee all facets of the Canadian subsidiary.

"It's really exciting for me to be given the opportunity to build another company within the Reproductive Endocrinology marketplace," said Jason Nestor. "GSN's technology offers revolutionary testing opportunities in the fertility industry and beyond, and I am looking forward to helping the company further expand its presence throughout the United States as the first company to offer highly accurate single cell gene implantation testing for genetic diseases using data informatics."

"Jason's experience and success building sales organizations, specifically in the reproductive health arena, makes him an invaluable asset. We've achieved a number of milestones in 2008 including the birth of the first babies following use of our test and partnership with over 25 IVF centers across the U.S. We're thrilled to have him on board as we work to further accomplish our strategic and financial goals. We're thrilled to have him as part of the GSN team," said Matthew Rabinowitz, PhD, Chief Executive Officer of Gene Security Network.

### About Gene Security Network

GSN's proprietary *Parental Support™* technology is the first to leverage data informatics to deliver highly accurate single cell testing for chromosome abnormalities and genetic diseases. *Parental Support™* uses genetic information from the parents, as well as HapMap data from the Human Genome Project, to clarify the typically noisy measurements from a single cell and to generate an in silico reconstruction of the cell's genotype. GSN operates a CLIA-certified laboratory in Redwood City, California and is funded by a highly respected group of venture



investors including Claremont Creek Ventures and Sequoia Capital. For more information, please visit [www.genesecurity.net](http://www.genesecurity.net).

Company Contact:

Jennifer Keller

[jkeller@genesecurity.net](mailto:jkeller@genesecurity.net)

650-249-9090 ext. 309

Press and Investor Contact:

Anne Bowdidge

650-218-6900